Fibrosis File-November-2009

  Fibrosis File InterMune, Inc. Files New Drug Application According to their press release, InterMune, Inc. announced that it submitted a New Drug Application (NDA) with the FDA, seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the…

Fibrosis File – May 2009

Fibrosis File Help from the Caring Voice Coalition The Caring Voice Coalition (CVC) remains available to people with Interstitial Pulmonary Fibrosis (IPF), Pulmonary Arterial Hypertension and Alpha-1 Antitrypsin Emphysema. Their services include: An Insurance Education and Assistance Program has one-on-one patient assistance with insurance reimbursement Financial support may be available to help patients keep and…

Fibrosis File – March 2009

Fibrosis File The Coalition for Pulmonary Fibrosis (CPF) is calling this a historic time in the research and treatment of IPF–Idiopathic Pulmonary Fibrosis – as a pivotal Phase III clinical trial has been completed for Pirfenidone and data released from Japan. The positive data could pave the way for the first FDA-approved therapy to treat…

Fibrosis File – May 2008

Fibrosis File Researchers from Japan may have a new treatment option for people with Idiopathic Pulmonary Fibrosis (IPF). Information presented at a recent American Thoracic Society Conference in Toronto involved a Phase III clinical trial in which investigators discovered that a daily dose of pirfenidone could improve lung function and slow the progression of IPF.…